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Abstract: Human cytomegalovirus (HCMV), a linear double-stranded DNA betaherpesvirus
belonging to the family of Herpesviridae, is characterized by widespread seroprevalence,
ranging between 56% and 94%, strictly dependent on the socioeconomic background of the country
being considered. Typically, HCMV causes asymptomatic infection in the immunocompetent
population, while in immunocompromised individuals or when transmitted vertically from the
mother to the fetus it leads to systemic disease with severe complications and high mortality
rate. Following primary infection, HCMV establishes a state of latency primarily in myeloid cells,
from which it can be reactivated by various inflammatory stimuli. Several studies have shown that
HCMV, despite being a DNA virus, is highly prone to genetic variability that strongly influences its
replication and dissemination rates as well as cellular tropism. In this scenario, the few currently
available drugs for the treatment of HCMV infections are characterized by high toxicity, poor oral
bioavailability, and emerging resistance. Here, we review past and current literature that has greatly
advanced our understanding of the biology and genetics of HCMV, stressing the urgent need for
innovative and safe anti-HCMV therapies and effective vaccines to treat and prevent HCMV infections,
particularly in vulnerable populations.
Keywords: human cytomegalovirus; genetic variability; viral dissemination; pathogenesis;
antiviral therapy
1. Introduction
Human cytomegalovirus (HCMV), also called human herpesvirus 5 (HHV-5), is one of the
nine herpesviruses capable of successfully infecting humans. HCMV belongs to the Group I of the
Baltimore classification, and specifically to the subfamily Betaherpesvirinae within the Herpesviridae
family (Table 1) [1].
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Table 1. Classification of human herpesviruses.
Subfamily Genus Species Tropism Global Prevalence (%)
Alphaherpesvirinae
Simplexvirus
Varicellovirus
Human herpesvirus 1
(HHV-1)/Herpes simplex
virus type 1 (HSV-1)
Human herpesvirus 2
(HHV-2)/Herpes simplex
virus type 2 (HSV-2)
Human herpesvirus 3
(HHV-3)/Varicella zoster
virus (VZV)
Mucoepithelial cells
(mainly oro-facial tract),
neurons
Mucoepithelial cells
(mainly genital tract),
neurons
Mucoepithelial cells,
T cells, neurons
40–90
10–60
50–95
Betaherpesvirinae
Cytomegalovirus
Roseolovirus
Human herpesvirus 5
(HHV-5)/Human
cytomegalovirus
(HCMV)
Human herpesvirus 6A
(HHV-6A)
Human herpesvirus 6B
(HHV-6B)
Human herpesvirus 7
(HHV-7)
Epithelial cells,
monocytes, lymphocytes,
fibroblasts, and more
Epithelial cells, T cells,
fibroblasts
Epithelial cells, T cells,
fibroblasts
Epithelial cells, T cells,
fibroblasts
56–94
60–100
40–100
44–98
Gammaherpesvirinae
Lymphocryptovirus
Rhadinovirus
Human herpesvirus 4
(HHV-4)/Epstein-Barr
virus (EBV)
Human herpesvirus 8
(HHV-8)/Kaposi’s
sarcoma associated
herpesvirus (KSHV)
Mucoepithelial cells,
B cells
Lymphocytes
80–100
6–50
The expression of HCMV genes, similar to that of all other herpesviruses, occurs in a temporal
cascade consisting of immediate-early (IE), early (E), and late (L) genes. The viral particles are formed
by a double-stranded DNA (dsDNA) genome (~230 kb), an icosahedral capsid, followed by the
tegument (a proteinaceous layer), and a coating known as pericapsid or envelope, which confers the
virion a quasi-spherical shape (Figure 1), a feature shared with all other herpesviruses.
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HCMV can infect a broad cell range that includes epithelial cells of glandular and mucous tissues,
smooth muscle cells, fibroblasts, macrophages, hepatocytes, dendritic cells, and vascular endothelial
cells (ECs) [2]. After primary infection, similar to other members of the herpesvirus family, HCMV can
establish latency in the host that can be reversed even after many years by any number of stimuli [3,4].
A typical characteristic of HCMV, which originally granted the virus its name, is that of forming
in the infected cell a voluminous intranuclear inclusion body and one or more intra-cytoplasmic
inclusion bodies, the so-called “owl’s eye” inclusions, made up of clusters of newly formed viruses and
lysosomes. The formation of such bodies generally results in increased cellular volume, a phenomenon
defined as cytomegaly. Studies on HCMV began in the early 1900s when particular attention was paid
to the owl’s eyes found in biopsies from stillborn fetuses and later in the kidneys and parathyroid
gland cells of organ transplant patients [4].
HCMV efficiently spreads through infected body fluids, and it can also be transmitted vertically
from the mother to the fetus through the placenta, causing congenital pathologies. Furthermore,
even when the primary infection is resolved by an effective cellular immune response, a population of
latently infected myeloid cells can persist in bone marrow monocyte precursors, thereby contributing
to the risk of transferring HCMV along with organs and tissues following transplantation.
HCMV is a common pathogen of global clinical relevance, with worldwide seroprevalence
ranging from 56% to 94% [5]. The viral spread in the global population is enormous, mainly due to the
asymptomatic mode of infection, followed by a constant shedding of the virus through body fluids
(e.g., milk, saliva, cervical secretions, and tears), which can last for months or even years.
HCMV is particularly dangerous for the following target categories of individuals [6]:
(i) immunocompetent hosts, where it causes asymptomatic infections or a slight form of
mononucleotic-like pathology; (ii) immunocompromised individuals such as patients suffering from
human immunodeficiency virus (HIV) or undergoing bone or organ transplants; and (iii) congenitally
infected newborns, who can be infected in utero, postnatally, or via breastfeeding. Of note, the prevalence
of congenital HCMV (cHCMV) disease is much higher than that of Down syndrome, spina bifida,
or fetal alcohol syndrome [7].
The host immune status ultimately determines the outcome of the infection as
immunocompromised conditions predispose the patient to a primary infection or determine the
reactivation of a latent one. In this regard, HCMV is notoriously famous for its ability to cause
congenital anomalies and long-term neurological sequelae in newborns. Furthermore, it can also
trigger the development of serious pathologies in solid organ or stem cell transplant recipients that are
not always resolved by currently available antivirals, thereby leading in some cases to death [8].
This review provides a summary of the general characteristics of HCMV as well as its strain
variability, dissemination, latency, reactivation, pathogenesis, prevention, and treatment.
2. Pathogenesis
HCMV pathogenesis and clinical features of infection in various patient populations are
summarized below (Figure 2).
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2.1. Infection of Im unocompetent Adults
HCMV infection com only oc urs in healt lt c ildren, with a prevalence gradually
increasing with age [9]. When symptomatic, it re cleosis-like syndrome with a less
promine t cervical lymphadenopathy than that ca tein-Ba r virus (EBV) [10]. One of
the symptoms i rash, which only manifests in ononucleosis cases [11]. Noteworthy,
a minority of primary HCMV infections result in relapsing sympto s (i.e., fever, night sweats, fatigue,
myalgia, arthralgia, and transaminitis), which can last for several weeks [10] or, less frequently, lead
to multi-organ failure [12,13], even though the severe tissue-invasive disease is usually limited to
critically ill or immunodeficient patients [14]. A study describing the various clinical manifestations
of 290 immunocompetent patients with severe HCMV infection showed that the gastrointestinal
tract is the preferential organ affected, primarily in the form of colitis, followed by morbidities of the
central nervous system (CNS) (i.e., meningitis, encephalitis, and transverse myelitis), hematological
abnormalities (i.e., hemolytic anemia, and thrombocytopenia), the involvement of the eye (uveitis and
retinitis), liver (hepatitis), and lung (pneumonitis), and thrombosis of the arterial and venous system [15].
Although several studies have reported a rapid clinical improvement in immunocompetent patients
with severe HCMV infection after anti-HCMV therapy, criteria for specific antiviral pharmacological
treatments are not well established [12]. Randomized controlled trials should therefore be conducted
to determine in which cases anti-HCMV therapy in immunocompetent patients with symptomatic
HCMV infections is needed.
2.2. Infection of Immunocompromised Patients
In the immunocompetent host, HCMV and immunity coexist in a delicate balance. When the
host immune system is compromised—i.e., in individuals with acquired immune deficiency syndrome
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(AIDS) and other immune diseases, post-transplant and intensive care unit (ICU) patients, and, to some
extent, elderly people—the virus can exert its full pathogenic potential. Its reactivation in
immunocompetent hosts, which occurs intermittently throughout life, triggers a lifelong IgG-mediated
immunologic response that keeps in check viral replication. In contrast, uncontrolled viral replication
occurs when populations of HCMV-specific CD4+ and CD8+ T cells are not well preserved, as observed
in immunocompromised hosts, leading to severe clinical disease [16].
2.3. Cytomegalovirus and HIV
HIV-infected individuals are generally co-infected with HCMV [17]. Prior to the introduction
of highly active antiretroviral therapy (HAART) in developed countries, about 40% of HIV-infected
patients would suffer from severe HCMV disease [18]. Currently, durable suppression of HIV viremia
has increased the overall patient life quality and expectancy and reduced to a minimum the pathologies
associated with HCMV viral reactivation. Nevertheless, comorbidities remain problematic for HIV
patients. In this regard, a close relationship between HCMV infection and HIV persistence has been
reported. This is probably due to the fact that HIV-driven CD4+ T-cell loss and dysfunction may lead
to HCMV replication and subsequent expansion of CD8+ T cells. Indeed, an elevated number of
CD8+ T cells and a low CD4+/CD8+ T-cell ratio have been observed in individuals co-infected with
both viruses but not in patients infected with HIV or HCMV alone [19]. Fittingly, Hunt et al. [20]
demonstrated that CD8 T-cell activation could be reduced in HAART-treated HIV patients with
incomplete CD4 T-cell recovery by administering anti-HCMV drugs, attesting that HCMV plays
a significant role in immune activation in HIV patients. Moreover, persistent HCMV replication
modulated longevity and proliferation of HIV-infected cells, improved the recruitment of new HIV
target cells, and stimulated HIV transcription, thereby creating an HIV reservoir favoring AIDS
progression. Clinically, retinitis has been shown to be the predominant pathology in AIDS patients
(20–30%), and it usually appears at the late stages of the syndrome in patients with low CD4 count [21].
HCMV retinitis in HIV patients is commonly observed in two different forms: fulminant or indolent,
both characterized by minimal or completely absent vitreous and anterior chamber inflammation [22].
If left untreated, HCMV infection of retinal cells may cause subacute retinal destruction, which can
result in irreversible blindness. Paradoxically, HAART therapy while restoring the patient immune
system can lead to a new pathology, known as immune recovery uveitis (IRU), which is equally
destructive to the host tissue and deleterious to the quality of the patient’s life [23]. Following retinitis,
the most prevalent clinical manifestations are the following: colitis(in the US, 5–10% of HIV patients
with low CD4 lymphocyte counts were affected by enterocolitis prior to the availability of HAART
therapy [24]), esophagitis (most commonly due to co-infection with either herpes simplex virus or
Candida albicans), pneumonitis, encephalitis, hepatitis, and adrenalitis [25].
2.4. Cytomegalovirus and Transplant Patients
HCMV is one of the most frequently encountered opportunistic viral pathogens in transplant
patients: a primary infection can occur in seronegative individuals after organ transplantation while
a latent infection can be reactivated in seropositive individuals due to immunosuppressive treatment.
The risks of HCMV-related complications in transplant recipients (R) vary according to the serostatus
of the donor (D): HCMV D−/R− transplantation is classified as low-risk, HCMV D+/R+ or D−/R+ as
medium-risk, and HCMV D+/R− as high-risk [26,27]. The most prevalent clinical manifestations in
HCMV-transplanted patients are gastrointestinal symptoms, mainly affecting the upper digestive
tract, whereas diarrhea is a rare occurrence indicative of colon involvement. Meningoencephalitis,
clinical hepatitis, myocarditis, and pancreatitis are more common than respiratory symptoms, which in
fact indicate more severe disease and may require admission to an ICU. Transplant patients without
HCMV prophylaxis may display a spectrum of clinical manifestations that vary in severity from patient
to patient, depending on additional personal illness risk factors, type of transplant procedure,
the immunological match between donor and recipient, and immunosuppressive drugs being
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administered. For instance, patients treated with mammalian target of rapamycin (mTOR) inhibitors
display a very low incidence of HCMV. The incidence of HCMV also correlates with the type of
transplant: about 50% among pancreas or kidney–pancreas recipients, 50–75% in lung or heart–lung
recipients, 9–23% in heart recipients, 22–29% in liver recipients, and 8–32% in kidney recipients [28,29].
Moreover, in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT), HCMV can
lead to fatal infectious complications related to host immune recovery—about 30–70% of non-autologous
and 5% of autologous HSCT-patients develop HCMV disease. Pneumonia is the disease most highly
associated with HCMV infection of HSCT patients, frequently leading to death despite aggressive
treatment with antiviral agents and adjunctive therapies [30]. The reasons for the development of
different clinical sequelae among all the aforementioned types of transplanted patients is probably
due to a combination of the following factors: (i) the nature of the proinflammatory cytokine cocktail
arising after organ transplantation; (ii) the duration of HCMV replication—most transplant recipients
display acute HCMV infection, which subsequently results in disease in a relatively short time frame,
whereas, for example, congenitally infected infants and HIV patients can display high levels of HCMV
replication for several months; and (iii) the status of the immune system response. For instance,
HCMV pneumonitis only occurs when patients can activate their immune system [31].
Interestingly, conflicting results have been reported regarding the association between early
cytomegalovirus reactivation and relapse after HSCT. Some studies suggest that HCMV replication
after transplantation is associated with a decreased relapse risk [32–37], while others highlight
that HCMV’s protective effect is restricted to patients with acute myeloid leukemia (AML) [38,39]
and cannot be extended to patients with acute lymphoblastic leukemia (ALL) [40], lymphoma [41],
myelodysplastic syndrome (MDS) [42], or observed in pediatric leukemias [43]. Furthermore, a more
recent study by Peric et al. [44] reports that the protective HCMV effect has been pronounced in
patients with myeloproliferative malignancies, while, at the same time, confirming the fact that such
effect has not been observed in patients with lymphoproliferative disorders, in concordance with other
studies [40,41]. Moreover, the same study highlights a significant reduction of relapse in patients
with myeloproliferative neoplasms (MPN) associated with early CMV reactivation [44]. Finally, some
evidence suggests that the beneficial effect of HCMV is mostly related to the conditioning regimen
and restricted only to patients who receive myeloablative chemotherapy (MAC) before undergoing
HSCT [45]. Despite the mounting evidence, the impact of HCMV reactivation on the patients’ overall
survival (OS) has been largely regarded as controversial due to its known negative effect on non-relapse
mortality (NRM). Thus, it remains largely unclear whether these conflicting reports can provide
a more detailed insight into the distinct protective mechanism or they simply reflect other variables,
including the sample size of the studied transplant groups. Therefore, larger prospective studies
with a significant follow-up on all patients with different malignancies, monitored and treated in
a homogeneous manner are needed to fully elucidate the underlying mechanism responsible for the
exact effect of HCMV reactivation. These findings may ultimately lead to a significant improvement in
patient management, donor selection strategies, or more personalized preemptive treatment of HCMV
infection in posttransplant patients with particular malignancies.
2.5. Congenital and Neonatal Infection
HCMV is the major infectious cause of congenital abnormalities. The incidence of cHCMV
infection due to primary and non-primary maternal HCMV infection is ~0.4–0.8% in developed
countries. In general, the risk of transmission correlated with the stage of pregnancy is higher in later
stages and lower in earlier ones, but in either case HCMV infection is generally associated with severe
clinical sequelae in the fetus. In developed countries, ~40% of women in reproductive age are HCMV
seronegative, 1–3% of whom may contract primary HCMV infection during pregnancy. The most
vulnerable groups include adolescents, mothers, and caregivers in close contact with young children
(e.g., teachers, nurses, etc.). Primary maternal HCMV infection has a 30–40% risk of transmission to the
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fetus. Importantly, HCMV reactivation or reinfection can also occur in women who are seropositive
prior to pregnancy, but, in such cases, the rate of HCMV transmission is only ~1% [46,47].
The hypothesis that pre-existing maternal immunity may favor low HCMV transmission rates
has long been debated. In this regard, Coppola et al. [48] performed a systemic review of the literature
using Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) [49] guidelines
and identified 19 studies assessing congenital HCMV birth prevalence in HCMV-seropositive mothers.
All these studies reported low levels of congenital HCMV birth prevalence (0.4–0.6%) in seropositive
mothers, in good agreement with previous findings by Lanzieri et al. [50], who systematically reviewed
postnatal HCMV prevalence in developing countries. Moreover, 11 studies reported HCMV maternal
seroprevalence and HCMV birth prevalence rates of 84–100% and 0.6–6.1%, respectively.
Even though most infants with cHCMV are asymptomatic, they may develop health problems
at birth or later. In the most severe cases, cHCMV can cause the death of the unborn baby. In all
other cases, the most clinically relevant signs at birth may include microcephaly, hepatosplenomegaly,
retinitis, intrauterine growth restriction, seizures, rash, and jaundice. Some children with cHCMV
infection may also suffer from long-term health problems, such as hearing loss, which can be present at
birth or may develop later even in asymptomatic infants, developmental and motor delay, vision loss,
and seizures. Cognitive impairment and retinitis have also been observed in asymptomatic children
but at much lower rates compared to symptomatic children [51]. Prevention of HCMV remains elusive
given the lack of drugs capable of treating HCMV infection in pregnant women. This aspect, together
with the fact that maternal immunity has a protective role against cHCMV infection, suggests that
vaccine development remains the most viable option to avoid HCMV vertical transmission.
3. Dissemination
HCMV exploits both vertical and horizontal transmission. Vertical transmission occurs through
the placenta [52–54], during birth (with genital secretions), or postnatally through breast milk [55–57].
Horizontal transmission takes place via organ transplant [58,59], blood transfusion, or direct contact
with contaminated body fluids, such as urine, breast milk, and genital secretions [60–62].
In most of these cases, because they cover all body surfaces, epithelial cells of the skin and internal
mucosa are the first site of HCMV infection. For instance, infection through breastfeeding starts
from the oral mucosa, moves to the gastrointestinal tract, which can support a productive infection,
and eventually disseminates throughout the body. In contrast, studies using murine CMV (MCMV)
have shown that, after oral/intranasal inoculation, the infection can only evolve in the upper respiratory
tract but not in the gut [63]. It remains a matter of debate how HCMV disseminates from the upper
respiratory tract throughout the body.
It is widely acknowledged that HCMV can spread systemically via leucocytes, a process associated
with short-duration viremia, during which infection of the lungs, liver, and spleen occurs primarily
through viral dissemination [64]. Subsequent secondary dissemination leads to the infection of salivary
glands, breast, and kidneys, all secretion-producing organs that release the virus into the environment
for months, even years, favoring intra-host transmission [64]. According to a model whereby primary
dissemination produces many viral particles that then infect other organs generating even more
virus progeny, it would be expected a gradual increase in viral burden during primary infection [64]
(Figure 3).
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He e, he pithelial cells are often the first sit of infecti n and from there HCMV infects leuco ytes
that traffic around the body. This is correlated with a p ocess called primary vira isse ination that
lea s to the infection of multiple tissu s, such as lungs, liver, and spleen. Afterwards, secondary viral
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glands and kidneys, which shed the virus.
However, animal studies using the MC V model showed a biphasic rather than a gradual increase
in viremia, suggesting a much more complex scenario [65].
Recently, Jackson and Sparer [66] demonstrated that cells of the upper respiratory tract, once
infected, release not only viral progeny but also chemotactic factors. According to the proposed model,
these chemokines trigger the recruitment of innate immune cells, which after being infected further
spread the virus to secondary organs and body fluids [66]. Fittingly, HCMV DNA has never been found
in the form of free circulating viral particles, except for highly fragmented DNA [67]. Consistent with
the lack of free circulating HCMV, leukocyte-depleted blood from seropositive donors prior to blood
transfusion prevents HCMV transfer [68,69], indicating that HCMV viremia is mostly cell-associated.
More recently, Farrell et al. [63] showed that the first cells to be infected after nasal inoculation with
MCMV are alveolar macrophages and type 2 alveolar epithelial cells. Entry into epithelial cells and
macrophages occurs through endocytosis and is followed by subsequent pH-dependent fusion with
the endosomal membrane, mediated by the viral envelope glycoproteins gB and gH/gL/gO and the
pentameric complex formed by gH/gL/UL128, UL130 and UL131A [70,71]. Then, the local spread
is thought to occur through direct cell-to-cell transmission, mediated in part by the HCMV gene
US28 [72].
The main cell types contributing to hematog nous dissemi ation, a beit to different extents,
include polymorphonuclear cells (PMNs), monocytes, ECs, and dendritic cells. After recruitment to the
first site of infection, these cells are highly prone to infection themselv s, thereby becoming tential
vehicles for HCMV transmission, even though most of them are unable to support a complete viral
replication cycle [73–76]. Consistently, HCMV is frequently found in PMNs from immunocompromised
patients [74], in which viral replication is generally abortive and non-productive [73]. The infection
of PMNs most likely occurs by transient microfusion between ECs and PMNs after an initial direct
contact mediated by the pentameric complex. Successively, infected PMNs transfer the virus particles
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to other cell types [77]. On the other hand, other studies using MCMV do not seem to support the
hypothesis that neutrophils play a role in HCMV dissemination, since their depletion did not alter
primary or secondary viral diffusion [78], whereas depletion of monocytes, macrophages, and NK
led to reduced viral dissemination [63,79,80]. However, it is important to point out that there are
substantial differences between human and murine CMV, exemplified by the lack of the MCMV CXC
chemokine homolog involved in neutrophil migration [78].
HCMV carries two genes, UL146 and UL147, which encode for the two chemokine homologs
vCXCL-1 and vCXCL-2, respectively, involved in the recruitment of innate immune cells [81–84].
pUL128, a key component of the pentameric complex, is an important chemokine that, once released in
the extracellular milieu, regulates monocyte migration [85]. Likewise, MCK2 in MCMV acts as a strong
attractant of monocytes, which appear to be conserved dissemination vehicles across species [86,87].
Monocyte-driven hematogenous spread is probably the result of the close proximity of these cells to
the vascular epithelium, which renders them particularly susceptible to infection with viral particles
originating from productively infected ECs. Once fully differentiated into tissue macrophages [75],
they can, in turn, spread the infection to the organs where they transmigrated [88–90].
Infected ECs also play a fundamental and active role in HCMV dissemination. In fact, HCMV
infection of ECs supports viral replication and promotes the enhanced expression of the adhesion
molecules ICAM-1 and vCAM-1 [91,92], as well as increased vascular permeability, which promotes
recruitment of leucocytes, direct contact [92] and migration through the endothelial layer.
Dendritic cells (DCs) are antigen-presenting cells that keep in check foreign pathogens by
influencing T-cell activation and differentiation in the draining lymph node through different
mechanisms [93]. Immature DCs localize in all mucosal and epidermal surfaces of the body where they
uptake HCMV infectious particles, thereby initiating the maturation process during their migration to
the draining lymph node. Upon localization in this new site, the newly mature and permissive DCs
are capable of transferring the virus to other cells [94].
In summary, there is still certainly a long way to go before we can fully understand the pathogenesis
of HCMV infection, but the aforementioned mechanism of HCMV dissemination proposed by Jackson
and Sparer [66] appears to be putting together many pieces of the puzzle.
4. Latency
Viral latency is defined as the maintenance of the viral genome without any production of
infectious progeny until this dormant genome can reactivate in response to specific stimuli and initiate
a productive infection. It is, therefore, becoming increasingly clear that a better understanding of latency
and subsequent reactivation may be crucial to elucidate HCMV pathogenesis and develop therapeutics
targeting latent virus reservoirs. This is a particularly important aspect given that all commercially
available drugs for the treatment of HCMV diseases only target lytic but not latent infections.
For decades, latency was considered as a silent state of the infection, characterized by overall
suppression of viral gene expression aimed at preventing the detection and activation of the immune
system. However, several recent studies have shown latency to be a dynamic phase of the infection,
where viral gene expression triggers a transcriptional cascade responsible for subverting host cell
functions, such as cell survival, genome carriage, and immune evasion [95–97].
The main site where HCMV is known to establish latency is in cells of the myeloid lineage.
The idea that infectious viral particles could be carried by white blood cells came from the observation
that blood transfer from healthy seropositive donors to immunosuppressed seronegative recipients
often resulted in HCMV disease [98–100], and that transfusion of leukocyte-depleted blood reduced
the incidence of HCMV disease [101].
However, it was only thanks to the increased sensitivity of the PCR technique that HCMV DNA
could be found in naturally latently infected peripheral blood mononuclear cells (PBMCs), in particular
monocytes and CD34+ progenitor cells isolated from the bone marrow [102,103]. Consistent with the
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notion of myeloid cells being a bona fide site of latency, HCMV IE RNA expression has also recently
been detected in DCs isolated from peripheral blood of healthy individuals [104].
Investigations on viral gene expression during natural infection are limited by the fact that
only 0.004–0.01% of mononuclear cells from seropositive granulocyte colony-stimulating factor
(G-CSF)-stimulated donors carry viral genomes, with a low copy number of 2–13 genomes per infected
cell, as judged by PCR-driven in situ hybridization [105]. For this and other reasons, leukemic
cell line models such as THP-1 and CD34+ Kasumi 3, as well as several embryonic stem cell lines,
have been preferentially used as bona fide and low-cost models to study latency and reactivation
in vitro [106–109].
As CD34+ cells are also lymphoid cell progenitors, several studies have tried to explain why
myeloid cells are then the only cell lineage able to carry latent viral genome. By performing
experimentally latent HCMV infection of CD34+ progenitor cells, Poole et al. [110] observed an increase
in the cellular transcription factor GATA-2, a key regulator of myeloid differentiation, suggesting
that the virus may only engage myeloid-committed cells, promoting their survival. GATA-2 is also
involved in the differentiation of hematopoietic progenitors along the endothelial lineage. However,
HCMV DNA could not be detected by PCR in ECs from the saphenous vein of healthy individuals,
contrary to the hypothesis that microvasculature is a site of HCMV latency [111].
To establish latency, HCMV must stop the production of infectious viral particles through
suppression of viral gene expression and, at the same time, induce the expression of latency-associated
viral genes [112–116]. One of the key events required to initiate a state of latency involves the repression
of the viral major immediate-early promoter (MIEP), which is sufficient to prevent the expression of E
and late L genes as well. Transcriptional inactivation of this region is achieved through induction of
repressive chromatin marks—e.g., histones methylation and recruitment of heterochromatin protein
1 (HP-1)—and repressive transcription factors [117]. Concurrently, differentiation of latent CD34+
cells or monocytes to macrophages or DCs induces re-activation of the promoter through histone
acetylation and loss of HP-1, with subsequent expression of IE genes and re-entry into the lytic
cycle [76,104,118,119], indicating that dynamic regulation of the MIEP is a first and crucial step to
control latency/reactivation.
One of the most widely accepted hypotheses is that the virus gene expression upon latency is
mainly characterized by a robust suppression and shut down of almost all viral genes, an expression
profile similar to that of the late lytic cycle. In this regard, it has been proposed that, in latently infected
cells, the timely transcriptional cascade of productive infection may be prematurely interrupted by
cellular mechanisms. Alternatively, there could be, right after viral entry, early induction of viral gene
expression followed by massive repression of viral transcription [120].
As mentioned above, rather than being quiescent, latent HCMV infection induces the expression
of a certain amount of viral genes. The most sophisticated mechanism for modulating the host cell
environment without attracting an immune response is mediated by non-immunogenic molecules,
such as small RNA transcripts. Assessing both experimentally and naturally latent infected cells by
next-generation sequencing, Rossetto et al. [121] identified two long non-coding (nc) RNAs (lncRNAs),
RNA4.9 and RNA2.7, and mRNAs encoding replication factors UL84 and UL44. Of note, RNA lnc4.9 in
concert with latently expressed UL84 was shown to interact with members of the polycomb repressor
complex 2 (PRC2), which potentially represents an additional step of silencing of the MIEP through
their histone methyltransferase activity [122].
Across its genome, HCMV also encodes at least 20 viral microRNAs (miRNAs) identified first
in lytically-infected cells [123], but also in latently-infected cells THP-1 by Meshesha et al. [124],
using deep-sequencing analysis. More recently, two similar studies were performed using instead
primary latently-infected cells that more resemble the in vivo situation, even though they showed
conflicting results to some extent [125,126]. The advantage of using miRNAs, besides their
non-immunogenic state, stems from their ability to modulate the expression of multiple targets
involved in immune evasion, survival, and proliferation of HCMV-infected cells, as well as virus
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reactivation [127]. One example is the miR-UL148D that during the lytic cycle promotes T-cell
chemotaxis by targeting CCL5 (RANTES), while during latency it may trigger activin signaling,
thereby inhibiting pro-inflammatory cytokine secretion [126,128]. In addition, even cellular miRNAome
was shown to be widely affected by HCMV latent infection [129].
A restricted amount of viral proteins is detected in naturally latent infected cells, even though their
exact role in latency is only partially clear. These include: US28, a constitutively activated chemokine
receptor acting as a chemokine sink [130]; viral IL-10, which can downregulate MHC II surface
expression and modulate CD4+ T-cell recognition [131], UL144, a decoy tumor necrosis factor receptor
(TNFR), which inhibits T cell proliferation in vitro [132] and subverts the TH1 immune response in
a TNF ligand-independent fashion [133]; LUNA (latency unique natural antigen), a protein required
for reactivation [134]; and UL138, which maintains latent infection and suppresses reactivation [115].
Interestingly, this latter is a potentially druggable target in latently infected cells as it inhibits a cellular
drug transporter [134].
As latency appears to be a very complex phenomenon, reactivation is often the result of a closely
intertwined crosstalk between cellular and viral signals triggering multiple pathways. Indeed, IE gene
expression alone does not seem to be sufficient to induce the production of infectious particles [76].
In this regard, the observation that differentiation of experimentally latently infected monocytes into
monocyte-derived macrophages can lead to a fully permissive phenotype [88,89] implies that the
differentiation status is a critical determinant of reactivation. In addition, mounting evidence indicates
that inflammation may also play a role in HCMV reactivation. For instance, virus reactivation has
been observed in several progenitor cell types under a variety of inflammatory conditions [135–137],
and HCMV disease prevalence is directly associated with highly inflammatory environments [137–139].
In light of the above, it is becoming increasingly evident how a multiplicity of latency and
reactivation pathways can determine the course of HCMV infection. These pathways appear to be
independent of the clinical strains but seemingly dependent on a combination of viral and cellular
factors working cooperatively to cross the threshold for reactivation of latently infected cells (Figure 4).
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Figure 4. Latency. Following primary infection, HCMV can establish latency in CD34+ myeloid
progenitor cells and is carried down the myeloid lineage. In latently-infected CD34+ cells and
monocytes, there is a targeted suppression of lytic viral gene expression. HCMV utilizes several viral
proteins and small RNA transcripts, including viral and cellular miRNAs, during latent infection to
alter the signaling environment within the cell to maintain the status of latency. Differentiation of
these cells to macrophages and DCs causes the derepression of the MIEP and allows initiation of the
lytic tr nscriptio prog am, whi h i volves a te poral casc de of viral gene transcription, allowing
reactivation of de novo virus production. HCMV, human cytom galovirus; DC, dendritic cell; HSC,
hematopoietic stem cell; lncRNA, long non-coding RNA; IE, immediate-early; E, early; L, late.
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5. HCMV Strain Variation
The massive spread of HCMV infection and the wide spectrum of disease manifestations in
infected patients sparked a major interest in determining the origin and mechanisms of HCMV
pathogenicity. It has been 66 years since Margaret Gladys Smith isolated for the first time MCMV from
salivary glands and propagated the virus in mouse cell culture—such strain is still in use and commonly
called “Smith strain” [140]. One year later, she succeeded in growing submaxillary salivary-derived
HCMV in human cell culture. As early as 1960, Thomas Weller isolated the so-called David strain
from a liver biopsy and managed to identify serological differences between cytomegalic inclusion
disease (CID) isolates [141].. Subsequently, five different HCMV clinical isolates were sequenced
(FIX GenBank AC146907; TR GenBank KF021605; PH GenBank AC146904; Toledo GenBank AC146905;
Merlin GenBank AY446894). The pioneering work on sequencing of the complete genome of an HCMV
laboratory strain (AD169 GenBank AC146999) [142], along with numerous in vitro findings and data
from several vaccine studies, revealed the existence of a substantial genetic variation among HCMV
strains. In particular, the highly passaged laboratory strains AD169 and Towne (GenBank FJ616285)
appeared attenuated when administered as vaccine candidates [143,144]. By contrast, the Toledo
strain, which had only been passaged several times in culture, caused disease when administered to
seropositive individuals [145]. Taken together, these findings suggest that the pathogenic potential of
HCMV was correlated with the genetic composition of each distinct strain.
The differences among the widely used laboratory strains AD169, Towne, and Toledo were localized
to multiple ORFs in the UL/b′ region of the genome, encoding viral proteins with immunomodulatory
or evasive functions [145,146]. Those genes that were lost upon extensive passaging in vitro played
a crucial role in promoting viral replication and immune manipulation in vivo [147]. Consistently,
extensive culture passaging led to the selection of HCMV mutants lacking these genes within weeks of
propagation, and it also gave rise to variations between commonly used laboratory strains [146,148–150].
In the following years, with the development of more sensitive sequencing techniques, such as
Sanger and high-throughput sequencing [151,152], a higher number of HCMV genomes were sequenced
from bacterial artificial chromosomes [153–155], virion DNA [156], or overlapping PCR amplicons [148].
The widespread implementation of these new techniques allowed assessing different aspects of
HCMV genome variation in clinical HCMV isolates from different cohorts of infected patients,
thus providing novel insights into the genetic variation upon natural infection. Up to date, the complete
genomes of 351 full-length HCMV strains have been published and analyzed (National Institute of
Allergy and Infectious Diseases (NIAID)-sponsored Virus Pathogen Database and Analysis Resource
(ViPR) [157]) [158]. Interestingly, these sequencing data show that HCMV can be highly polymorphic
among and within hosts [159–161], with a high level of intra-host variability comparable to that of RNA
viruses [159]. Given the fact that HCMV is a large double-stranded DNA virus, a high degree of genetic
variation contradicted the logical expectation that the virus would retain high genome stability [162].
This unexpected intra-host HCMV diversity was initially attributed to the rapid occurrence of de novo
mutations [159,160]—i.e. new mutations occur every time the virus infects a new host, thereby giving
rise to a unique viral strain for each infected individual. Eventually, HCMV infection triggers
a selection event where a new genotype becomes dominant due to the selective pressure of the immune
response [159]. An alternative explanation was based on the evidence that viral and host factors
can contribute to the onset of HCMV genome mutations, thus fostering virus genetic drift upon
infection [163,164]. However, more recent data indicate that in non-mixed infections the mutation
rate of HCMV is no different from that of other DNA viruses, while HCMV acquires a high degree of
variability upon mixed infections [165–167], extensive recombination [152,166–168], or reactivation of
the latent virus within a single individual. Many of these genetic alterations may in turn influence
HCMV cell tropism, immune evasion, and disease outcomes. Indeed, the contribution of superinfection
and recombination to viral genetic variability, an intensively debated topic, could have important
ramifications in viral evolution, immune adaptation, and pathogenesis, especially in congenital or
transplant patients [169,170].
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Substantial efforts have been undertaken by various groups to correlate infection outcomes with
variation in HCMV-specific genes [145,171,172]. Even though the selection of these genes was based
on data supporting their potential role in viral pathogenicity and dissemination, these studies were
only limited to Sanger sequencing of polymerase chain reaction (PCR) amplicons and often focused on
a small number of polymorphic (hypervariable) genes. Furthermore, in such cases, low-abundance
viral populations might have been missed, and the overall viral diversity underestimated. Thus, future
studies should take advantage of high-throughput sequencing for fast detection and characterization
of multiple-strain infections. Ideally, as recently put forward by Davison and co-workers, the definition
of HCMV natural populations should be carried out by whole genome sequencing of HCMV strains
directly from clinical samples [166].
6. Prevention
Although the development of an HCMV vaccine had already started in the 1970s, research in
HCMV vaccine discovery received a major push when in 2000 the US Institute of Medicine placed
HCMV among the top priorities for vaccine development [173]. Despite these increasing efforts,
an effective vaccine against HCMV is currently missing, de facto leaving high-risk populations, chiefly
immunocompromised patients and immunocompetent seronegative pregnant mothers, exposed to
primary infection [174]. Given that one of the main obstacles to the development of an efficient
vaccine against HCMV is the lack of protection against HCMV re-infection and/or reactivation, the first
objective of a newly designed HCMV vaccine should be that of shielding vulnerable populations
from primary infection. The long-range goal would then be to grant permanent protection against
new infections with other HCMV strains and reactivated infections, which can occur repeatedly
throughout life. To reach these goals, the ideal HCMV vaccine should be able to trigger a strong
humoral response, in the form of binding and neutralizing antibodies, and an HCMV-specific CD8+
and CD4+ T-cell response. With this in mind, the experimental and clinical results achieved so far
predict that the ideal HCMV vaccine should include: (i) gB, promoting both humoral—primarily
antibody-binding—and T-cell-mediated response [164]; (ii) pp65, triggering a potent T-cell response;
and (iii) the pentameric complex (PC), which prompts a quite strong neutralizing antibody (NAb)
response [175]. Indeed, PC-induced NAbs are powerful cell-to-cell spread viral inhibitors in numerous
cell types, not just fibroblasts. In the following sections, we summarize the most relevant approaches
for designing effective HCMV vaccines (Table 2).
Table 2. HCMV Vaccines. NAb, Neutralizing Antibody; HELF, human embryonic lung fibroblasts; PC,
pentameric complex; VLPs, virus like particles.
Live HCMV Vaccine Description Clinical Trials
Towne vaccine HCMV attenuated strain.
Phase I/II clinical studies evidences:
(a) no virus excretion;
(b) no virus latency;
(c) NAb induction;
(d) generation of both
HCM-specific CD4 and CD8 T-cell;
(e) partial protection against
a secondary infection.
Towne-Toledo chimera vaccines Genetic recombinant Towneand Toledo.
In Phase I clinical trials they were
well tolerated and with no virus
excretion. One chimera was more
immunogenic than Towne.
AD169 vaccine HCMV attenuated strain.
Patients did not to display
cell-mediated immunity depression
or any systemic reactions.
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Live HCMV Vaccine Description Clinical Trials
V160 vaccine Replication-defective virus vaccinebased on strain AD169.
Phase I study showed that
V160-immunized
HCMV-seronegative patients have
features comparable in quality to
those from seropositive subjects.
Viral vectored vaccines
Heterologous viral vectors used to
deliver HCMV-encoded antigens:
(a) canarypox virus vector;
(b) alphavirus vector [Venezuelan
equine encephalitis (VEE) virus];
(c) lymphocyte choriomeningitis
virus vector;
(d) modified vaccinia Ankara virus
(MVA) vector;
(e) adenovirus type 6 vector.
Many of them were tested in Phase
I/II trials. While viral vectors cannot
replicate completely when injected
into humans, they have an optimal
safety profile.
Non-living HCMV Vaccines
gB subunit vaccines Combination of the recombinantglycoprotein gB with an adjuvant.
Many Phase II studies showed that
gB/MF59 vaccine had a certain
degree of protection against HCMV
infection through the mucosal route,
but the antibody response was
short-lived and disappeared within
a year.
DNA based vaccines
Single or mixed combination of
plasmids encoding viral antigens
such as pp65, gB and IE1.
The most promising DNA-based
plasmid vaccine, called ASP0113
divalent DNA vaccine, is currently
in Phase III clinical trials.
RNA based vaccines
Different strategies:
(a) synthetic self-amplifying
mRNA expressing a pp65-IE1
construct and gB;
(b) mRNA-based multiantigenic
vaccine including pp65, gB and PC;
(c) lipid nanoparticle
(LNP)-encapsulated
nucleoside-modified mRNA
encoding full-length gB.
Currently they have been all tested
only on animal models.
VLPs vaccines
Enveloped virus-like particles
(VLPs) which exhibit on their
surface gB and, in some cases, PC.
Different variations of VLPs have
shown some success in animal
immunization tests.
Dense body vaccines Dense bodies purified from HCMVinfected cell.
DB-injected mice did display both
T-cell and NAb responses
6.1. Live HCMV Vaccines
The first attempts to develop an HCMV vaccine were focused on two attenuated strains: the AD169
and the Towne strain, both developed at the beginning of the 1970s by Elek and Stern in London
and Plotkin in Philadelphia [176,177]. Their results show the vaccine to be very safe due to the
absence of virus excretions—this was true even for vaccinated kidney transplant patients on chronic
immunosuppression. Furthermore, these patients did not display cell-mediated immunity depression
or any systemic reactions. Concerning immunogenicity, NAbs were present at levels similar to those
found in the serum of patients infected with the wild type virus. Although the vaccine was able to
generate both HCMV-specific CD8+ and CD4+ T-cell response, the immunity induced by vaccination
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did not prevent secondary infection in pregnant women, while mucosal immunity induced by natural
infection did. Thus, immunization was deemed incomplete [178]. A reason for this only partial success
is probably related to the fact that the two HCMV strains used to obtain the vaccines, when propagated
on fibroblasts in vitro, are known to acquire mutations in UL128L, a subunit of the pentameric complex.
In particular, the Towne strain undergoes a 2-bp insertion (TT), causing a frameshift mutation in
UL130 [154]. This event is particularly important if we consider that a functional PC is required for
the virus entry into epithelial cells or ECs, whereas gB and the gH/gL dimer are sufficient for entry
into fibroblasts [179]. Consistently, epithelial-neutralizing antibodies against Towne strain, harboring
a mutation in PC, were 28-fold lower than those induced by natural infection [180].
To develop a live HCMV vaccine with the same safety of the Towne’s one but more protective
and immunogenic, four genetic recombinants of Towne and Toledo, a low-passage HCMV strain,
were subsequently generated. The chimera vaccine candidates were tested in Phase I clinical trials and
found to be well tolerated and with no virus excretions in saliva or urine, with two chimeras (2 and 4)
being more immunogenic than Towne [181].
In 2012, a replication-defective virus strategy was put in place for the first time. It consisted of
restoring a mutated PC through serial passages of AD169-infected ECs. Subsequently, the two HCMV
proteins IE1/2 and UL51 were linked to a protein domain that rendered their stability dependent on
the synthetic compound Shield 1 (Shld1). That meant that HCMV could replicate normally in the
presence of Shld1, whereas in the absence of such molecule viral replication was abortive due to the
IE1/2 and UL51 degradation. As later confirmed in several studies, this defective virus, named V160,
retained its ability to express all other AD169-specific proteins, including PC and gB, thereby eliciting
both T cell and humoral responses in non-human primates as well as in humans [182]. A recently
concluded Phase I study showed that sera from V160-immunized HCMV-seronegative patients have
features similar in quality to those from seropositive subjects, justifying future clinical trials on this
vaccine [183].
Finally, several viral vectored vaccines against HCMV have been formulated and tested in Phase
I/II trials. These strategies for vaccine development employ heterologous viral vectors to deliver
HCMV-encoded antigens such as gB, pp65, IE1, and, in some cases, PC proteins. While viral vectors
cannot replicate completely when injected into humans, they have an optimal safety profile and can
efficiently carry the desired viral antigens. The following heterologous viral vectors were tested as
HCMV vaccines: canarypox virus vector, alphavirus vector (Venezuelan equine encephalitis (VEE)
virus), lymphocyte choriomeningitis virus vector, modified vaccinia Ankara virus (MVA) vector,
and adenovirus type 6 vector [184].
In conclusion, although consistent progress has been made over the past 45 years, and several
potential candidates have emerged, an effective live HCMV vaccine has yet to be successfully developed.
6.2. Non-Living HCMV Vaccines
The simplest non-living HCMV vaccines are the so-called subunit vaccines, obtained by combining
subunit immunogens with an adjuvant. The first one was made with the recombinant glycoprotein
gB with the microfluidized adjuvant 59 (MF59) [185]. Several Phase II clinical trials in both adults
and toddlers showed that after three doses given at 0, 1, and 6 months gB/MF59 was able to induce
a reasonable NAb titer. Even though these studies showed that gB when injected alone as a vaccine
had a certain degree of protection against HCMV infection through the mucosal route, the antibody
response was short-lived and disappeared within a year [186].
A different strategy for non-living vaccines is based on genetic programming of host
cells—via uptake of naked DNA or RNA—to express the desired immunogens in vivo. In this
regard, a plasmid-based DNA vaccine, called the ASP0113 bivalent DNA vaccine, managed to reach
Phase III clinical trials. This vaccine was obtained using two plasmids: VCL-6365, encoding the
extracellular domain of gB, and VCL-6368, encoding a modified pp65 protein kinase gene [187].
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Likewise, the use of self-replicating RNA to express viral proteins has made progress in recent
years. Specifically, an mRNA-based multiantigenic vaccine containing gB, pp65, and PC injected in mice
was capable of inducing potent cell-mediated and humoral immune responses. Although an effective
cell response to pp65 was hampered by the presence of other HCMV antigens, it could be restored
by sequential immunization of pp65 followed by PC + gB + pp65 [188]. In a very recent study
a new RNA-based vaccine, consisting of lipid nanoparticle (LNP)-encapsulated nucleoside-modified
mRNA encoding full-length gB, was tested on a group of young New Zealand White rabbits. The gB
nucleoside-modified mRNA-LNP vaccines were highly immunogenic with similar kinetics and
comparable peak gB-binding and functional antibody responses induced by gB/MF59 subunit vaccine.
However, rabbits immunized with nucleoside-modified mRNA-LNP showed significantly longer
duration of vaccine-induced antibody responses [189].
Other heavily studied approaches include the use of HCMV peptides, to elicit cellular immunity
in transplant patients, and enveloped virus-like particles (VLPs) in order to stimulate wild type viruses
in the absence of viral DNA, with VLPs exhibiting on their surface gB and, in some cases, PC different
variations of VLPs have had some success in animal immunization tests [190,191].
One different approach involves the purification of dense bodies (DBs), including virion tegument
and envelope proteins but not viral genome, produced by HCMV-infected cells. DB-injected mice did
display both T-cell and NAb responses [192].
In summary, the antigens needed for successful vaccination against HCMV are well known from
the literature. Thus, further effort will be required in combining such antigens to achieve a durable
response that would protect an individual for an extended time.
7. Treatment
The high incidence and clinical manifestations of HCMV infection underscore the need for
efficient antiviral therapies in treating disease in immunocompromised patients and congenitally
infected infants.
Four compounds are currently approved for systemic treatment or prophylaxis of HCMV infections:
ganciclovir (GCV) and its oral prodrug valganciclovir (VGCV), cidofovir (CDV), foscarnet (FOS),
and, more recently, letermovir (LTV) [193,194] (Table 3).
Table 3. Antiviral agents approved for treatment or prevention of HCMV infections.
Agent CompoundInformation Viral Target
Mechanism of
Action
Route of
Administration Dosage Toxicities
Ganciclovir
(Cytovene®)
Acyclic nucleoside
analogue of guanine UL54
When
phosphorylated to
Ganciclovir
triphosphate
inhibits the viral
DNA polymerase
UL54
Intravenous
Oral
Induction:
5 mg/kg every
12 hours for
7–14 days
Maintenance:
5 mg/kg for
100–120 days
after transplant
FDA approved
for maintenance
therapy only
using 1 mg three
times a day
Neutropenia
Thrombocytopenia
Neurotoxicity
Valganciclovir
(Valcyte®)
L-Valyl ester of
Ganciclovir UL54
Converted to
Ganciclovir in
intestine and liver,
inhibits the viral
DNA polymerase
Oral
Induction:
900 mg twice
a day for 21 days
Maintenance:
900 mg once
per day
Granulocytopenia
Anemia
Thrombocytopenia
Cidofovir
(Vistide®)
Deoxycytidine acyclic
nucleotide
phosphonate analog
UL54
When
phosphorylated to
Cidofovir
biphosphate
inhibits the viral
DNA polymerase
Intravenous
Induction:
5 mg/kg weekly
for 2 weeks
Maintenance:
5 mg/kg every
2 weeks
Nephrotoxicity
Metabolic acidosis
Ocular hypotony
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Agent CompoundInformation Viral Target
Mechanism of
Action
Route of
Administration Dosage Toxicities
Foscarnet
(Foscavir®)
Synthetic organic
analogue of inorganic
pyrophosphate
UL54
Inhibits activity of
pyrophosphate
binding site on
viral DNA
polymerase UL54
Intravenous
Induction:
60 mg/kg every
8 hours for
14–21 days
Maintenance:
90–120 mg/kg
everyday
Nephrotoxicity
Hypocalcemia
Electrolytes
imbalance
Genital ulceration
Letermovir
(Prevymis®)
Non-nucleoside,
3,4-dihydroquinazolinyl
acetic
pUL56
Binds pUL56
subunit of the
HCMV terminase
complex
preventing the
cleavage of
concatemeric
DNA
Intravenous
Oral
Prophylaxis:
480 mg once
a day, through
100 days
post-transplant
Among the latter, GCV, CDV, and FOS exhibit similar activities, as they target viral DNA
polymerases, consequently inhibiting the synthesis of HCMV DNA [195]. In contrast, LTV blocks DNA
packaging in the viral capsid by interfering with the viral terminase complex [196]. Furthermore, in the
late 1990s, a fifth antiviral compound, fomivirsen, also known as Vitravene, was approved for the
treatment of HCMV infection by the Food and Drug Administration (FDA) and the European Agency
for the Evaluation of Medicinal Products (EMEA). Fomivirsen, an antisense 21-mer phosphorothioate
oligonucleotide (5′-GCGTTTGCTCTTCTTCTTGCG-3′) complementary to the mRNA encoding the
IE-2 protein, is used to treat HCMV-induced retinopathy in immunocompromised subjects [197].
Prophylactic treatment with acyclovir has also been approved in some countries, although the
effectiveness of this approach is moderate.
The front-line therapy for HCMV infections is GCV, which was approved for medical use in 1988
and is now routinely used to treat congenitally HCMV-infected infants [198] and immunocompromised
hosts with HCMV disease [199] or given as a prophylactic agent to prevent HCMV disease [194,200,201].
GCV, a monosodium salt of 9-(1,3-dihydroxy-2-propoxymethyl)-guanine, is an acyclic nucleoside analog
administered by intravenous infusion that, when phosphorylated to form GCV triphosphate (GCV-TP),
inhibits the viral UL54 DNA polymerase and, by competing with deoxyguanosine (dGTP), curbs the
elongation of viral DNA. GCV is administered in an inactive form and is selectively phosphorylated
in the infected cells by the HCMV UL97 kinase [202]. This kinase is responsible for the conversion
of GCV to GCV monophosphate (GCV-MP), while the subsequent phosphorylation steps generating
the active form of the drug (GCV-TP) are controlled by cellular kinases [203]. However, its moderate
antiviral activity and dose-limiting toxicity hinder its efficacy and may lead to the development of
drug-resistant infections, mainly in immunocompromised patients [204]. Specifically, GCV-induced
cytotoxicity may result in thrombocytopenia and neutropenia in transplant recipients [205].
Secondary therapies for HCMV infections consist of CDV and FOS, which can both cause
nephrotoxicity and give rise to resistant infections [193,194].
CDV was approved in 1996 for the treatment of HCMV retinitis in AIDS patients and is available
only intravenously. Cidofovir, 1-[(S)-3-hydroxy-2-(phosphonomethoxy) propyl]cytosine, is an acyclic
phosphonate nucleoside (ANP) acting as an analog of CMP (cytidine monophosphate). CDV presents
a broad spectrum of antiviral activity; in particular, it acts against most DNA viruses (e.g., herpesviruses,
adenovirus, polyomavirus, and orthopoxvirus) [206]. Since CDV is a monophosphate analog, it does
not require the initial activating phosphorylation by the UL97 viral kinase. Nevertheless, to be
active, CDV needs to be diphosphorylated by the pyruvate kinase, creatine kinase and nucleoside
diphosphate kinase, all present at high levels in infected HCMV cells. Once activated, CDV competes
with deoxycytidine triphosphate and is incorporated in the DNA as an alternative substrate of the
viral DNA polymerase where it acts as a non-mandatory chain terminator [206]. CDV resistance is
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only associated with viral DNA polymerase mutations and occurs at a frequency comparable to that of
GCV [206].
FOS was approved for the treatment of HCMV infections in 1991. Similar to CDV, FOS inhibits
the replication of several types of DNA viruses (e.g., several herpes family viruses, hepatitis B virus,
and HIV), but it is primarily used for the treatment of HCMV retinitis [207]. FOS is a synthetic organic
analog of inorganic pyrophosphate, which reversibly inhibits the activity of the UL54 DNA polymerase.
FOS resistance during long-term therapy occurs at similar rates to those displayed by CDV and GCV.
However, FOS can be particularly useful against some GCV-resistant infections as the frequency of
GCV cross-resistance is much lower than that observed for CDV and GCV, even though renal toxicity
may limit its usefulness [208]. Combination therapy with GCV has also been investigated, but it does
not seem to be more efficient than GCV alone. Despite the above limitations, the broad spectrum
of antiviral activity of FOS makes this compound useful for the treatment of some GCV-resistant
infections. Of note, FOS has also been approved for the treatment of ACV-resistant HSV infections.
Lastly, because this agent crosses the blood-brain barrier, it is indicated for the treatment of viral
infections involving the central nervous system.
Drug resistance results from the development of single or multiple mutations leading to different
levels of resistance that can reduce the efficacy of the antiviral treatments. Since all these drugs, except
of fomivirsen, target, directly or indirectly, viral DNA polymerase, the emergence of drug-resistant
HCMV strains, often due to mutations in UL97 and/or UL54, has increasingly hampered disease
management [209]. Therefore, there is an urgent medical need for new anti-HCMV agents with new
mechanisms of action and fewer side effects.
Currently, a promising new class of riboside analogs with strong and specific antiviral activity
against HCMV is being tested in a clinical trial. One of these drugs is maribavir, a benzimidazole
riboside characterized by a novel mechanism of action based on its ability to inhibit UL97, a viral enzyme
that blocks nuclear egress of viral capsids, and to interfere with viral DNA synthesis. Even though
clinical trials with maribavir have not yet been conclusive, the drug is still being evaluated as a potential
preventive treatment of HCMV infection [210,211].
BAY 38-4766, also called tomeglovir, is a non-nucleoside antiviral. The antiviral activity of BAY
38-4766 is due to its ability to hinder DNA maturation most likely by targeting the UL89 and UL56
genes encoding for the subunits of a multiprotein complex involved in HCMV termination [212].
Interestingly, in a guinea pig model, after infection and treatment, measurable amounts of the compound
were detected in fetal blood, attesting that the drug is capable of crossing the placenta in pregnant
animals [213]. BAY 38-4766 is in clinical development and has shown a positive safety profile in healthy
male volunteers at single oral doses of up to 2000 mg. However, no recent studies have highlighted the
current state of clinical development of this drug or related compounds in the series [213].
GW275175X is a new benzimidazole riboside class of HCMV inhibitors that can block the
maturational cleavage of high molecular weight HCMV DNA by interacting with pUL56 and pUL89,
the two subunits of the HCMV terminase complex [214]. GW275175X was advanced to Phase I clinical
trial with an increasing dose of safety, pharmacokinetics, and tolerability, but was later set aside to
prioritize maribavir testing. The clinical potential of this antiviral still requires further study.
Brincidofovir (CMX001), a prodrug of CDV, is an oral lipid-drug conjugate quickly absorbed
into cells whereupon the lipid side chain is cleaved, releasing CDV to be further phosphorylated by
intracellular kinases to CDV diphosphate. Since brincidofovir is not a substrate for the oxyanion
transporter in the kidney, kidney damage should be reduced. Nonetheless, CDV may lead to
gastrointestinal toxicity, which is quite often dose-limiting [215].
In 2017, LTV became the latest FDA-approved drug for prophylaxis of HCMV infections in
allogeneic HSCT recipients [216]. LTV is a non-nucleoside 3,4-dihydroquinazolinyl acetic acid,
which can be administered orally or intravenously infused. LTV acts as an inhibitor of the HCMV
DNA terminase complex by interacting with the pUL56 subunit of such complex and preventing the
cleavage of concatemeric DNA into monomeric genome length DNA, which ultimately inhibits DNA
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packaging into the virion. LVT displays good efficacy against different clinical isolates of HCMV,
including GCV-resistant strains, and is ineffective against all other herpesviruses [217].
To sum up, evidence from the literature indicates that currently available anti-HCMV drugs,
despite being able to interfere with viral replication through different mechanisms of action, are often
associated with multiple side effects such as drug toxicity, poor oral bioavailability, and drug resistance.
Therefore, innovative compounds targeting new virus components with fewer adverse effects are
urgently needed to improve patient outcomes.
8. Conclusions
HCMV is the leading cause of congenital infections resulting in severe morbidity and mortality
among newborns worldwide. This virus is highly polymorphic, particularly in genes contributing
to immune modulation. Despite a large amount of HCMV research over the past few decades,
the mechanisms and virulence factors contributing to HCMV pathogenesis and particular clinical
outcomes remain unclear. To make matters worse, to date, no safe vaccines against HCMV infections
exist and current antiviral therapies are quite unsatisfactory due to the frequent occurrence of drug
resistance and toxicity.
Overall, the lack of advances in the treatment of HCMV-driven diseases clearly clashes with the
widespread notion that HCMV poses “a greater threat to infants than other viruses”. Thus, an in-depth
understanding of HCMV-host interactions, especially at the individual level, will be instrumental to
develop new diagnostic/therapeutic tools for the clinical management of this viral disease.
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